The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity

Cancer Cell

Volumn 18, Issue 2, 2010, Pages 160-170

  Park, SaeGwang ^a,b,c   Jiang, Zhujun ^a   Mortenson, Eric D ^b   Deng, Liufu ^a   Radkevich Brown, Olga ^b   Yang, Xuanming ^a   Sattar, Husain ^b   Wang, Yang ^a   Brown, Nicholas K ^b   Greene, Mark ^d   Liu, Yang ^e   Tang, Jie ^a   Wang, Shengdian ^a   Fu, Yang Xin ^a,b  

^a INSTITUTE OF BIOPHYSICS   (China)

^b UNIVERSITY OF CHICAGO   (United States)

^c Inje University College of Medicine   (South Korea)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Cellcycle; Cellimmuno; Molimmuno

Indexed keywords

CD8 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ERLOTINIB; FC RECEPTOR; MONOCLONAL ANTIBODY; NEU DIFFERENTIATION FACTOR; PACLITAXEL;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER RELAPSE; CANCER RESISTANCE; CD8+ T LYMPHOCYTE; CLEARANCE; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; INNATE IMMUNITY; MEMORY CELL; MICROENVIRONMENT; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; TUMOR REGRESSION;

EID: 77955534002     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2010.06.014     Document Type: Article

References (43)

1. Aomatsu T., Komatsu H., Yoden A., Hosomi A., Miyazaki H., Sogo T., Inui A., Fujisawa T., Tamai H. Fulminant hepatitis B and acute hepatitis B due to intrafamilial transmission of HBV after chemotherapy for non-Hodgkin's lymphoma in an HBV carrier. Eur. J. Pediatr. 2010, 169:167-171.
2. Apetoh L., Ghiringhelli F., Tesniere A., Obeid M., Ortiz C., Criollo A., Mignot G., Maiuri M.C., Ullrich E., Saulnier P., et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 2007, 13:1050-1059.
3. Arnould L., Gelly M., Penault-Llorca F., Benoit L., Bonnetain F., Migeon C., Cabaret V., Fermeaux V., Bertheau P., Garnier J., et al. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?. Br. J. Cancer 2006, 94:259-267.
4. Burgdorf S., Scholz C., Kautz A., Tampe R., Kurts C. Spatial and mechanistic separation of cross-presentation and endogenous antigen presentation. Nat. Immunol. 2008, 9:558-566.
5. Chen G.Y., Tang J., Zheng P., Liu Y. CD24 and Siglec-10 selectively repress tissue damage-induced immune responses. Science 2009, 323:1722-1725.
6. Clynes R.A., Towers T.L., Presta L.G., Ravetch J.V. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat. Med. 2000, 6:443-446.
7. Dhodapkar K.M., Krasovsky J., Williamson B., Dhodapkar M.V. Antitumor monoclonal antibodies enhance cross-presentation of cellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. J. Exp. Med. 2002, 195:125-133.
8. Emens L.A., Machiels J.P., Reilly R.T., Jaffee E.M. Chemotherapy: friend or foe to cancer vaccines?. Curr. Opin. Mol. Ther. 2001, 3:77-84.
9. Fan Z., Yu P., Wang Y., Wang Y., Fu M.L., Liu W., Sun Y., Fu Y.X. NK-cell activation by LIGHT triggers tumor-specific CD8+ T-cell immunity to reject established tumors. Blood 2006, 107:1342-1351.
10. Gennari R., Menard S., Fagnoni F., Ponchio L., Scelsi M., Tagliabue E., Castiglioni F., Villani L., Magalotti C., Gibelli N., et al. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin. Cancer Res. 2004, 10:5650-5655.
11. Hudis C.A. Trastuzumab-mechanism of action and use in clinical practice. N. Engl. J. Med. 2007, 357:39-51.
12. Ishihara Y., Harada M., Azuma K., Tamura M., Shomura H., Fujii T., Itoh K., Shichijo S. HER2/neu-derived peptides recognized by both cellular and humoral immune systems in HLA-A2+ cancer patients. Int. J. Oncol. 2004, 24:967-975.
13. Jacob J., Radkevich O., Forni G., Zielinski J., Shim D., Jones R.F., Wei W.Z. Activity of DNA vaccines encoding self or heterologous Her-2/neu in Her-2 or neu transgenic mice. Cell. Immunol. 2006, 240:96-106.
14. Kalergis A.M., Ravetch J.V. Inducing tumor immunity through the selective engagement of activating Fcgamma receptors on dendritic cells. J. Exp. Med. 2002, 195:1653-1659.
15. Kiessling R., Wei W.Z., Herrmann F., Lindencrona J.A., Choudhury A., Kono K., Seliger B. Cellular immunity to the Her-2/neu protooncogene. Adv. Cancer Res. 2002, 85:101-144.
16. Kim K.D., Zhao J., Auh S., Yang X., Du P., Tang H., Fu Y.X. Adaptive immune cells temper initial innate responses. Nat. Med. 2007, 13:1248-1252.
17. Le X.F., Lammayot A., Gold D., Lu Y., Mao W., Chang T., Patel A., Mills G.B., Bast R.C. Genes affecting the cell cycle, growth, maintenance, and drug sensitivity are preferentially regulated by anti-HER2 antibody through phosphatidylinositol 3-kinase-AKT signaling. J. Biol. Chem. 2005, 280:2092-2104.
18. Lee Y., Auh S.L., Wang Y., Burnette B., Meng Y., Beckett M., Sharma R., Chin R., Tu T., Weichselbaum R.R., Fu Y.X. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood 2009, 114:589-595.
19. Liao S., Ruddle N.H. Synchrony of high endothelial venules and lymphatic vessels revealed by immunization. J. Immunol. 2006, 177:3369-3379.
20. Machiels J.P., Reilly R.T., Emens L.A., Ercolini A.M., Lei R.Y., Weintraub D., Okoye F.I., Jaffee E.M. Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res. 2001, 61:3689-3697.
21. Meric-Bernstam F., Hung M.C. Advances in targeting human epidermal growth factor receptor-2 signaling for cancer therapy. Clin. Cancer Res. 2006, 12:6326-6330.
22. Mittendorf E.A., Liu Y., Tucker S.L., McKenzie T., Qiao N., Akli S., Biernacka A., Meijer L., Keyomarsi K., Hunt K.K. A novel interaction between HER2/neu and cyclin E in breast cancer. Oncogene 2010, 29:3896-3907.
23. Moasser M.M. Targeting the function of the HER2 oncogene in human cancer therapeutics. Oncogene 2007, 26:6577-6592.
24. Montgomery R.B., Makary E., Schiffman K., Goodell V., Disis M.L. Endogenous anti-HER2 antibodies block HER2 phosphorylation and signaling through extracellular signal-regulated kinase. Cancer Res. 2005, 65:650-656.
25. Musolino A., Naldi N., Bortesi B., Pezzuolo D., Capelletti M., Missale G., Laccabue D., Zerbini A., Camisa R., Bisagni G., et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J. Clin. Oncol. 2008, 26:1789-1796.
26. Park J.M., Terabe M., Steel J.C., Forni G., Sakai Y., Morris J.C., Berzofsky J.A. Therapy of advanced established murine breast cancer with a recombinant adenoviral ErbB-2/neu vaccine. Cancer Res. 2008, 68:1979-1987.
27. Pegram M., Hsu S., Lewis G., Pietras R., Beryt M., Sliwkowski M., Coombs D., Baly D., Kabbinavar F., Slamon D. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 1999, 18:2241-2251.
28. Pegram M.D., Konecny G.E., O'Callaghan C., Beryt M., Pietras R., Slamon D.J. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J. Natl. Cancer Inst. 2004, 96:739-749.
29. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., Goldhirsch A., Untch M., Smith I., Gianni L., Baselga J., Bell R., Jackisch C., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 2005, 353:1659-1672.
30. Rafiq K., Bergtold A., Clynes R. Immune complex-mediated antigen presentation induces tumor immunity. J. Clin. Invest. 2002, 110:71-79.
31. Romond E.H., Perez E.A., Bryant J., Suman V.J., Geyer C.E., Davidson N.E., Tan-Chiu E., Martino S., Paik S., Kaufman P.A., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 2005, 353:1673-1684.
32. Rovero S., Amici A., Carlo E.D., Bei R., Nanni P., Quaglino E., Porcedda P., Boggio K., Smorlesi A., Lollini P.L., et al. DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J. Immunol. 2000, 165:5133-5142.
33. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182.
34. Stagg J., Sharkey J., Pommey S., Young R., Takeda K., Yagita H., Johnstone R.W., Smyth M.J. Antibodies targeted to TRAIL receptor-2 and ErbB-2 synergize in vivo and induce an antitumor immune response. Proc. Natl. Acad. Sci. USA 2008, 105:16254-16259.
35. Taylor C., Hershman D., Shah N., Suciu-Foca N., Petrylak D.P., Taub R., Vahdat L., Cheng B., Pegram M., Knutson K.L., Clynes R. Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy. Clin. Cancer Res. 2007, 13:5133-5143.
36. Urbonaviciute V., Furnrohr B.G., Meister S., Munoz L., Heyder P., De Marchis F., Bianchi M.E., Kirschning C., Wagner H., Manfredi A.A., et al. Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE. J. Exp. Med. 2008, 205:3007-3018.
37. Varchetta S., Gibelli N., Oliviero B., Nardini E., Gennari R., Gatti G., Silva L.S., Villani L., Tagliabue E., Menard S., et al. Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2. Cancer Res. 2007, 67:11991-11999.
38. Wang Y.G., Kim K.D., Wang J., Yu P., Fu Y.X. Stimulating lymphotoxin beta receptor on the dendritic cells is critical for their homeostasis and expansion. J. Immunol. 2005, 175:6997-7002.
39. Wei W.Z., Jacob J.B., Zielinski J.F., Flynn J.C., Shim K.D., Alsharabi G., Giraldo A.A., Kong Y.C. Concurrent induction of antitumor immunity and autoimmune thyroiditis in CD4+ CD25+ regulatory T cell-depleted mice. Cancer Res. 2005, 65:8471-8478.
40. Whittington P.J., Piechocki M.P., Heng H.H., Jacob J.B., Jones R.F., Back J.B., Wei W.Z. DNA vaccination controls Her-2+ tumors that are refractory to targeted therapies. Cancer Res. 2008, 68:7502-7511.
41. Yu P., Lee Y., Liu W., Chin R.K., Wang J., Wang Y., Schietinger A., Philip M., Schreiber H., Fu Y.X. Priming of naive T cells inside tumors leads to eradication of established tumors. Nat. Immunol. 2004, 5:141-149.
42. Yu P., Lee Y., Wang Y., Liu X., Auh S., Gajewski T.F., Schreiber H., You Z., Kaynor C., Wang X., Fu Y.X. Targeting the primary tumor to generate CTL for the effective eradication of spontaneous metastases. J. Immunol. 2007, 179:1960-1968.
43. Zhang H., Wang Q., Montone K.T., Peavey J.E., Drebin J.A., Greene M.I., Murali R. Shared antigenic epitopes and pathobiological functions of anti-p185(her2/neu) monoclonal antibodies. Exp. Mol. Pathol. 1999, 67:15-25.